KR20090129981A - 항혈전 활성을 갖는 이미노이미다조피리딘 유도체 - Google Patents

항혈전 활성을 갖는 이미노이미다조피리딘 유도체 Download PDF

Info

Publication number
KR20090129981A
KR20090129981A KR1020097002137A KR20097002137A KR20090129981A KR 20090129981 A KR20090129981 A KR 20090129981A KR 1020097002137 A KR1020097002137 A KR 1020097002137A KR 20097002137 A KR20097002137 A KR 20097002137A KR 20090129981 A KR20090129981 A KR 20090129981A
Authority
KR
South Korea
Prior art keywords
alkyl
alkylene
formula
het
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020097002137A
Other languages
English (en)
Korean (ko)
Inventor
우베 하이넬트
아르민 호프마이슈터
외르크 체흐
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20090129981A publication Critical patent/KR20090129981A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097002137A 2006-08-02 2007-07-18 항혈전 활성을 갖는 이미노이미다조피리딘 유도체 Abandoned KR20090129981A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006036023.0 2006-08-02
DE102006036023A DE102006036023A1 (de) 2006-08-02 2006-08-02 Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität

Publications (1)

Publication Number Publication Date
KR20090129981A true KR20090129981A (ko) 2009-12-17

Family

ID=38884850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002137A Abandoned KR20090129981A (ko) 2006-08-02 2007-07-18 항혈전 활성을 갖는 이미노이미다조피리딘 유도체

Country Status (23)

Country Link
US (1) US7863269B2 (cg-RX-API-DMAC7.html)
EP (1) EP2054412B1 (cg-RX-API-DMAC7.html)
JP (1) JP5149897B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090129981A (cg-RX-API-DMAC7.html)
CN (1) CN101495478B (cg-RX-API-DMAC7.html)
AR (1) AR062158A1 (cg-RX-API-DMAC7.html)
AT (1) ATE450537T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007280780B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663332C (cg-RX-API-DMAC7.html)
CL (1) CL2007002240A1 (cg-RX-API-DMAC7.html)
DE (2) DE102006036023A1 (cg-RX-API-DMAC7.html)
DK (1) DK2054412T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2007000120A (cg-RX-API-DMAC7.html)
ES (1) ES2336044T3 (cg-RX-API-DMAC7.html)
IL (1) IL196789A (cg-RX-API-DMAC7.html)
MX (1) MX2009000408A (cg-RX-API-DMAC7.html)
MY (1) MY148611A (cg-RX-API-DMAC7.html)
NO (1) NO20090741L (cg-RX-API-DMAC7.html)
PE (1) PE20080687A1 (cg-RX-API-DMAC7.html)
PT (1) PT2054412E (cg-RX-API-DMAC7.html)
TW (1) TWI400240B (cg-RX-API-DMAC7.html)
WO (1) WO2008014888A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152040A (en) * 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (cg-RX-API-DMAC7.html) 1971-03-15 1976-07-24
DE2221796A1 (de) 1972-05-04 1973-11-15 Kraemer Kg Wilhelm Batteriebehaelter fuer stabbatterien
JPS60161986A (ja) * 1983-12-24 1985-08-23 Nippon Soda Co Ltd イミダゾ(1,5−a)ピリジン−3−オン誘導体及びその製造方法
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
RU2270192C2 (ru) * 2001-04-19 2006-02-20 Эйсай Ко., Лтд. Производные 2-иминопирролидина
EP1982984B1 (en) 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
EP1602646A4 (en) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
DE10353205A1 (de) 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
US7317124B2 (en) 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates

Also Published As

Publication number Publication date
US7863269B2 (en) 2011-01-04
PT2054412E (pt) 2010-02-04
CN101495478A (zh) 2009-07-29
DK2054412T3 (da) 2010-04-19
NO20090741L (no) 2009-02-16
WO2008014888A3 (de) 2008-06-12
DE102006036023A1 (de) 2008-02-07
TWI400240B (zh) 2013-07-01
US20090192150A1 (en) 2009-07-30
ES2336044T3 (es) 2010-04-07
JP2009545542A (ja) 2009-12-24
DE502007002219D1 (de) 2010-01-14
TW200821308A (en) 2008-05-16
JP5149897B2 (ja) 2013-02-20
EP2054412A2 (de) 2009-05-06
MY148611A (en) 2013-05-15
AR062158A1 (es) 2008-10-22
MX2009000408A (es) 2009-01-27
AU2007280780A1 (en) 2008-02-07
HK1135694A1 (en) 2010-06-11
IL196789A0 (en) 2009-11-18
IL196789A (en) 2012-07-31
PE20080687A1 (es) 2008-07-24
CA2663332A1 (en) 2008-02-07
CA2663332C (en) 2015-06-02
CN101495478B (zh) 2013-03-27
AU2007280780B2 (en) 2012-03-29
BRPI0714599A2 (pt) 2013-04-09
WO2008014888A2 (de) 2008-02-07
ATE450537T1 (de) 2009-12-15
CL2007002240A1 (es) 2008-02-08
DOP2007000120A (es) 2008-02-29
EP2054412B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
US8466169B2 (en) SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments
KR20090050081A (ko) 응고 인자 IXa 억제제로서 사용하기 위한 이소세린 유도체
KR20100114514A (ko) Par1 억제제로서의 트리아졸로피리다진, 이의 제조방법 및 약제로서의 용도
JP5570434B2 (ja) Par1阻害剤としてのイミダゾピリダジン類、その製造、及び薬剤としての使用
RU2446160C2 (ru) Тартратные производные для применения в качестве ингибиторов фактора свертывания крови ixa
US7863269B2 (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
HK1135694B (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
HK1148956B (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
HK1137419B (en) Tartrate derivatives for use as coagulation factor ixa inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120717

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140120

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140729

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee